Nautilus Biotechnology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating expenses | $66.8M | $81.5M | $76.2M | $63.6M | $50.5M |
| Cash from operations | -$50.7M | -$59.1M | -$51.7M | -$45.8M | -$39.2M |
| Capital expenditure | $1.3M | $2.1M | $2.4M | $2.3M | $2.3M |
| Free cash flow | -$52.0M | -$61.3M | -$54.2M | -$48.1M | -$41.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $191.1M | $242.7M | $305.6M | $350.1M | $398.4M |
| Total liabilities | $34.1M | $34.0M | $40.2M | $35.1M | $34.9M |
Shares outstanding 127.1M · Free float 71.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.